

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

Strategic Trading Analysis

Based on the detailed PDF report provided, here is my analysis as a Positional Equity Trader.

Step 1: Audit the Data

- **Data Present:**
 - **Price Action:** Daily, Weekly, and 15-min charts (candlesticks).
 - **Trend Indicators:** EMA (20, 50, 200), Supertrend, Golden Cross status.
 - **Momentum:** RSI, MACD, Relative Strength (RS) against benchmark.
 - **Volatility:** Bollinger Bands, Squeeze analysis, ATR.
 - **Fundamentals:** Revenue/Net Income trends, Analyst Estimates.
 - **Volume:** Volume bars, Moving Averages, Distribution days.
- **Data Missing:**
 - **Real-time market depth:** (Bid/Ask spread) - standard for PDF reports.
 - **Sector specific rotation:** While sector comparison exists, broader sector rotation maps are absent.
- **Confidence Level: High.** The report is comprehensive, covering technical structure, momentum, and fundamental context.
 - *Note:* The report date is generated as **2026-02-07**. I will treat this as "Current Market Price" (CMP) for the sake of this analysis.

Step 2: Analyze the Setup

Price Structure & Trend:* **Support Cluster:** The stock is trading at **INR 1191**, sitting directly on top of a massive confluence of support. The EMA 20 (1179), EMA 50 (1178), and EMA 200 (1162) are all tightly clustered below the current price. This "stacking" of moving averages acts as a strong floor.* **Trend:** The trend status is a **"Strong Uptrend"**. The stock recently confirmed a **Golden Cross** (50 EMA crossing above 200 EMA), which is a classic intermediate-term bullish signal.* **Supertrend:** On the Weekly and Daily timeframes, the Supertrend is **Green (Buy)**. The Daily buy signal triggered recently at INR 1119.

Momentum & Strength:* **RSI:** At **52.06**, RSI is neutral. It is not overbought, leaving significant room for upside expansion before hitting the 70 level.* **Relative Strength:** This is the weak point. The RS Score is **52/100** and it is classified as a "Weakening Leader." The stock is lagging the pharma index slightly (1Y RS < 1.0). This suggests it is a "value/recovery" trade rather than a "high momentum" breakout trade.* **MACD:** The histogram is positive, and the MACD line is above the signal line. While momentum is described as "weakening," the crossover remains bullish.

Volume & Volatility:* **Volume:** Current volume (805k) is below the 20-day average (1.2M). The stock needs an injection of volume to break overhead resistance.* **Bollinger Bands:** The price is in the upper half of the bands. The bands are relatively tight (width 0.10), suggesting a potential volatility expansion (move) is imminent.

Thesis:The setup is a **"Pullback to Support"** play. The stock has rallied, consolidated, and is now resting

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

on the 20/50/200 EMA cluster. As long as it holds INR 1160, the path of least resistance is up toward previous structural highs.

Step 3: Formulate the Recommendation

Verdict: YES (With strict risk management due to low volume).

The risk-to-reward ratio is highly favorable here because the stop loss can be placed very close to the entry (just below the EMA cluster), while the target offers >10% upside.

- **Entry Price: INR 1190 - INR 1200** (Current Market Price).
 - *Rationale:* Entering here capitalizes on the support provided by the EMA 20 and 50.
- **Stop Loss: INR 1155** (Daily Close basis).
 - *Rationale:* This is just below the 200 EMA (1162) and the Supertrend support. If the price closes below INR 1155, the "support cluster" thesis is invalidated, and the trend has reversed.
- **Take Profit: INR 1315**
 - *Rationale:* This aligns with the "Analyst Price Target" shown in the Trendlyne snapshot (INR 1319) and previous structural resistance zones visible on the weekly chart. This represents a **~10.5% upside**.

Risk Profile: * **Risk:** ~3.0% * **Reward:** ~10.5% * **R:R Ratio:** 1:3.5 (Excellent)

Candlestick Classification Analysis

Based on the **Candlestick Classification** report (Pages 20 & 21) and the specific logic provided, here is my analysis as a seasoned price action trader for **AUROPHARMA.NS**.

1. Current Classification: "No Control" (Score: 0)

The latest daily candle is classified as **"No Control"**. Using the algorithmic logic provided, this tells us a specific story about the session's price action:

- **Body Strength (Step 1):** The body size was likely **< 0.5 ATR** (Average True Range). This indicates a lack of conviction from both bulls and bears. The market opened and closed at very similar levels.
- **Wick Analysis (Step 3):** The presence of this classification suggests either **long wicks on both sides** (fighting for direction but failing) or a very tight range (dormant volatility).
- **Volume (Step 4):** The volume was likely **average or low (< 0.8x avg)**. If there had been a massive volume spike on a small body, it might have triggered a "churning" signal, but the "No Control" label implies a lack of institutional participation at this specific price point (INR 1191).

Trader's Take: The market is catching its breath. After the recent price swings, participants are stepping back to reassess value. This is a pause, not a reversal yet.

2. Trend Score Analysis (10-day avg): +0.10

The 10-day average score is **0.10**. This is a critical metric.* **Scale:** -2 (Strong Bear) to +2 (Strong Bull).*

Interpretation: A score of **+0.10** is effectively **Neutral with a whisper of Bullishness**.* **Context:** It means

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

that over the last two weeks, the sum of "Buyer Control" days and "Seller Control" days has almost perfectly zeroed out. The bulls have a microscopic edge, but they have failed to maintain dominance.

3. Visual Chart Analysis (Page 21)

Looking at the visual progression on the far right of the chart: 1. **Recovery Phase:** We saw a transition from "Seller Control" (Pink/Red) in late January to "Buyer Control" (Light Green) in early February. 2. **Stalling:** The most recent bars have turned Grey ("No Control") or Light Red ("Seller Control"). The failure to print a **"Buyer Strong Control" (Dark Green)** candle during the recent bounce is concerning. It implies the move up was driven by weak hands or short covering rather than aggressive institutional accumulation (High Volume + Large Body). 3. **Volume Confirmation:** Looking at the volume pane below the candles, the volume on the recent upward moves has been declining or average compared to the massive selling spikes seen in November/December 2025.

4. Future Price Prediction & Strategy

Verdict: Sideways Consolidation followed by a directional break.

The "No Control" signal acts as a coiled spring. The market rarely stays in "No Control" for long before volatility expands.

- **Immediate Direction (1-3 Days): Neutral/Choppy.** Expect the price to oscillate around the INR 1190 level. The lack of "Strong Control" means intraday traps are likely-breakouts will fail, and breakdowns will be bought.
- **The Bias: Slightly Bullish (Cautious).** Despite the "No Control" candle, the background trend (Supertrend on Page 10 is UP) and the fact that the Trend Score is positive (+0.10) gives the upside a slight probability advantage **IF** support holds.

Scenarios to Watch:

1. **The Bullish Confirmation:** Watch for a candle closing above **INR 1200** with **"Buyer Strong Control" (+2)**.
 - *Logic:* We need a body > 1.5 ATR and Volume > 1.3x avg to confirm that institutions are back. If this happens, price heads toward INR 1230-1250.
2. **The Bearish Reversal:** If the next candle is **"Seller Control" (-1)** or **"Seller Strong Control" (-2)** closing below **INR 1170**.
 - *Logic:* This would negate the recent weak recovery and confirm that the "No Control" candle was actually a pause in selling distribution.

Conclusion: Do not chase the price here. The **"No Control"** classification is a "Wait and See" signal. The internal dynamics show a lack of conviction. Wait for a **High Volume (+1.2x multiplier)** candle to dictate the next true leg of the trend. Currently, the price is drifting, not driving.

News & Analyst Targets

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

As an investment firm stock research analyst, here is the latest research and update on **Aurobindo Pharma (AUROPHARMA)** for the week ending **February 7, 2026**.

1. Latest News for AUROPHARMA (Week of Feb 1 - Feb 7, 2026)

- **US FDA Inspection Update (Eugia Pharma Unit III):** On **February 6, 2026**, the US FDA completed an inspection of **Eugia Pharma Specialities Ltd.'s Unit III** (a wholly-owned subsidiary) located in Telangana. The inspection, which began on January 27, concluded with **11 observations**.
 - *Analyst Note:* The company has stated these observations are **procedural in nature** and they will respond within the stipulated timeframe. Aurobindo Pharma management has asserted that this inspection will not impact financial performance or operations.
- **Q3 FY26 Earnings Schedule:** The company has officially scheduled its Q3 earnings conference call for **Tuesday, February 10, 2026, at 8:30 AM IST**. The financial results are expected to be released to the exchanges on the evening of **February 9, 2026**.
- **Penicillin-G Policy Impact:** Early in the week (Feb 2-3), the stock saw significant activity and a gap-up opening. This was linked to the Indian government's notification imposing a **Minimum Import Price (MIP)** on Penicillin-G, 6-APA, and Amoxicillin.
 - *Significance:* Aurobindo is a key beneficiary of the PLI scheme for Penicillin-G. The MIP is seen as a protective move for domestic manufacturers against cheap imports, directly benefiting Aurobindo's ramp-up plans.

2. Brokerage Upgrades & Downgrades

- **Axis Securities:** In a strategy report dated **February 3, 2026**, Axis Securities highlighted Aurobindo Pharma as a recommended pick within the Pharma sector, citing it as a beneficiary of the positive trade sentiment and the "China Plus One" shift formalized by recent trade deals.
- **Motilal Oswal:** Maintained a **BUY** rating in their update on **January 29, 2026**, raising/maintaining their conviction ahead of the Q3 results.
- **MarketsMojo:** Currently maintains a **"Hold"** rating (downgraded from Buy in Dec 2025), citing mixed technical indicators despite recent price strength.

3. Other Impacting News

- **Government MIP Notification (Sector Positive):** The Directorate General of Foreign Trade (DGFT) imposed a Minimum Import Price on specific antibiotics. As Aurobindo is commissioning a massive Penicillin-G plant under the PLI scheme, this policy prevents dumping from competitors (like China) and ensures price stability for their new capacity. This is a major structural positive for the stock.
- **US-India Trade Sentiment:** Broader market news regarding a landmark India-US trade deal (reported Feb 3) has spurred buying interest in export-oriented pharma companies, with Aurobindo being a primary beneficiary due to its high US exposure.

4. Analyst Price Targets

Below is the summary of the latest price targets released by major brokerages in late January and early February 2026.

Brokerage / Analyst	Reco Date	Rating	Target Price (INR)	Upside Potential*
Motilal Oswal	Jan 29, 2026	BUY	1,430	~20%
ICICI Direct	Feb 02, 2026	BUY	1,375	~15%
Axis Direct	Feb 03, 2026	BUY	1,345	~13%

Stock Analysis Report

© 2026 Stock Research. All Rights Reserved.

Brokerage / Analyst	Reco Date	Rating	Target Price (INR)	Upside Potential*
Trendlyne Consensus	Feb 07, 2026	BUY	1,334	~12%
BOB Capital Markets	Jan 2026	BUY	1,316	~10%

**Upside potential is calculated based on the approximate trading price of INR 1,191 as of the close on Feb 6, 2026.*

Analyst View: The street is cautiously optimistic heading into the Feb 10th earnings. The focus will be on the **US sales trajectory**, the **resolution timeline for the Eugia Unit III observations**, and the **ramp-up guidance for the Penicillin-G project**.

Stock Detailed Analysis Report

AUROPHARMA.NS

Current Price: ₹1191.00

Generated: 2026-02-07 10:32

AUROPHARMA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	9.31%	10.33%
Net Income	Yes	Yes	9.86%	9.59%
ROE	No	Yes	0.41%	-0.31%
EPS	Yes	Yes	10.43%	9.79%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	-7.03%	1.23%
Net Income	No	-8.71%	-2.37%
ROE	Yes	4.52%	4.52%
EPS	No	4.00%	-3.39%

AUROPHARMA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Weakening Leader
RS Score:	52.1/100
:	

== RS RATIOS ==:

1M RS:	1.019 [Leader]
3M RS:	1.062 [Leader]
6M RS:	1.099 [Leader]
1Y RS:	0.957 [Neutral]
:	

== TURNAROUND ANALYSIS ==:


Turnaround Status:	Not Detected
:	

SIGNAL CRITERIA::


✗ Emerging RS:	Not accelerating
✓ Medium-term Lagging:	1Y=0.957 (≤ 1.0)
✗ Performance Improving:	Not improving

Relative Strength Analysis: AUROPHARMA.NS vs ^CNXPHARMA
Classification: Weakening Leader


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline



AUROPHARMA.NS - EMA Crossover Summary

EMA 20:	1179.82
EMA 50:	1178.86
EMA 200:	1162.05
Trend Status:	Strong Uptrend
Golden Cross Date:	2025-11-26 00:00:00+05:30
Golden Cross Price:	1227.40


AUROPHARMA.NS EMA Crossover Analysis



AUROPHARMA.NS - Bollinger Bands Summary

Current Price:	1191.00
Upper Band:	1231.15
Middle Band (SMA 20):	1170.86
Lower Band:	1110.58
%B:	0.6670
Band Width:	0.1030
Status:	Upper Half
Signal:	None


AUROPHARMA.NS Bollinger Bands (20, 2) Analysis



AUROPHARMA.NS - Supertrend Summary

Status:	UPTREND (Buy)
Supertrend Value:	1119.77
Signal Identified On:	2026-02-03

Supertrend Analysis for AUROPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




AUROPHARMA.NS - MACD Summary

MACD Line:	0.96
Signal Line:	-4.84
Histogram:	5.80
Trend:	Bullish
Momentum:	Weakening
Signal:	None

AUROPHARMA.NS Price






AUROPHARMA.NS MACD (12, 26, 9)



AUROPHARMA.NS - Volatility Squeeze Summary

BB Width:	0.1030
ATR:	39.7929
Total Signals:	29
Signal 1:	BB Squeeze at 2026-01-08 00:00:00+05:30 (Price: 1206.10)
Signal 2:	BB Squeeze at 2026-01-09 00:00:00+05:30 (Price: 1198.70)
Signal 3:	BB Squeeze at 2026-01-12 00:00:00+05:30 (Price: 1172.90)
Signal 4:	BB Squeeze at 2026-01-13 00:00:00+05:30 (Price: 1167.70)
Signal 5:	BB Squeeze at 2026-01-14 00:00:00+05:30 (Price: 1180.10)

AUROPHARMA.NS - Volatility Squeeze Analysis



AUROPHARMA.NS - RSI-Volume Summary

Current RSI:	52.06
Current Volume:	805359
Volume MA 20:	1248012
Bullish Divergences:	1
Bearish Divergences:	3
Bullish Div 1:	Date: 2025-02-03 00:00:00+05:30, Price: 1121.19
Bearish Div 1:	Date: 2024-08-30 00:00:00+05:30, Price: 1563.53
Bearish Div 2:	Date: 2025-10-13 00:00:00+05:30, Price: 1136.80

AUROPHARMA.NS RSI-Volume Divergence Analysis



AUROPHARMA.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status:

30 Signals Detected

:

2026-01-09 [-]:

Distribution Day

2026-01-16 [-]:

Distribution Day

2026-01-21 [+]:

Selling Exhaustion (Bullish Div)



2026-02-03 [-]:

Climax Volume (Churning)

2026-02-04 [-]:

Distribution Day

AUROPHARMA.NS - Volume Analysis



AUROPHARMA.NS - Candlestick Classification Summary

== CANDLESTICK CLASSIFICATION ==:

Latest Classification: **No Control**

Recent Trend Score (10-day avg): 0.10

:

Distribution:

No Control: 133

Seller Control: 52

Buyer Control: 36

Seller Strong Control: 3

Buyer Strong Control: 3

AUOPHARMA.NS - Candlestick Classification




Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	UPTREND (Buy)	1122.17	1191.0	2025-11-10
1 Day	UPTREND (Buy)	1119.77	1191.0	2026-02-03
15 Min	UPTREND (Buy)	1177.09	1191.0	2026-02-06

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Weakening	No Signal
1 Day	Bullish	Weakening	No Signal
15 Min	Bullish	Weakening	No Signal

AUROPHARMA.NS - 1 Week (Candlestick + EMAs)




AUROPHARMA.NS - 1 Day (Candlestick + EMAs)



AUROPHARMA.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - AUROPHARMA_main



Trendlyne Snapshot - AUROPHARMA_forecaster

Markets

STARFOLIO

Alerts

F&O

MF

Reports

Screeners

Subscribe

Superstars

Portfolio

Watchlist

Insider Trades

Results

Data Downloader

More

Search Stock, IPO, MF

India

A

MARKETS / SECTOR: PHARMACEUTICALS & BIOTECHNOLOGY / INDUSTRY: PHARMACEUTICALS / AUROBINDO PHARMA LTD.

Aurobindo Pharma Ltd.

NSE: AUROPHARMA | BSE: 524804

Turnaround Potential

In 4 Starfolio Baskets

1191.00

9.40 (0.80%)

817.3K

NSE+BSE Volume

NSE 06 Feb, 2026 3:31 PM (IST)

Watchlist

Portfolio

Alert

My Notes

TRADE STOCK

Board Meeting

The next board meeting for Aurobindo Pharma is on 09 Feb 2026 for the purpose of Quarterly Results

See details

Overview

FORECASTER

STOCK REPORT

Buy Sell Zone

F&O

Financials

News

Reports

Technicals

Shareholding

Deals

Corporate Actions

Alerts

About

Aurobindo Pharma - AUROPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 28 analysts

Aurobindo Pharma has a share price target of Rs 1319, revenue growth forecast of 4.7%, and profit growth estimate of 3.2% for FY26, based on top 28 analyst calls.

Aurobindo Pharma FORECASTER - Analyst Estimates

[FORECASTER DASHBOARD](#)